GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beam Therapeutics Inc (NAS:BEAM) » Definitions » Financial Strength

Beam Therapeutics (Beam Therapeutics) Financial Strength : 6 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Beam Therapeutics Financial Strength?

Beam Therapeutics has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Beam Therapeutics's interest coverage with the available data. Beam Therapeutics's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.14. As of today, Beam Therapeutics's Altman Z-Score is 1.84.


Competitive Comparison of Beam Therapeutics's Financial Strength

For the Biotechnology subindustry, Beam Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beam Therapeutics's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Financial Strength distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Financial Strength falls into.



Beam Therapeutics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Beam Therapeutics's Interest Expense for the months ended in Dec. 2023 was $0.0 Mil. Its Operating Income for the months ended in Dec. 2023 was $132.9 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $159.9 Mil.

Beam Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is

GuruFocus does not calculate Beam Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Beam Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Beam Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(12.778 + 159.911) / 1264.768
=0.14

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Beam Therapeutics has a Z-score of 1.84, indicating it is in Grey Zones. This implies that Beam Therapeutics is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 1.84 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beam Therapeutics  (NAS:BEAM) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Beam Therapeutics has the Financial Strength Rank of 6.


Beam Therapeutics Financial Strength Related Terms

Thank you for viewing the detailed overview of Beam Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Beam Therapeutics (Beam Therapeutics) Business Description

Traded in Other Exchanges
Address
238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Executives
Christine Bellon officer: Chief Legal Officer BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
Amy Simon officer: Chief Medical Officer BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
Giuseppe Ciaramella officer: President & CSO C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
John M. Evans director, officer: CEO C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Terry-ann Burrell officer: CFO C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
John Maraganore director 75 SIDNEY ST, CAMBRIDGE MA 02139
Graham K Cooper director C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Kathleen E Walsh director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Stephen C Knight director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Mark Fishman director C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Beam Therapeutics (Beam Therapeutics) Headlines

From GuruFocus

Beam Therapeutics to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-09-2022

Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

Beam Therapeutics to Participate in Upcoming May Investor Conferences

By sperokesalga sperokesalga 05-17-2023